Immunome (IMNM) Non-Current Deffered Revenue (2019 - 2024)

Immunome (IMNM) has 5 years of Non-Current Deffered Revenue data on file, last reported at $2.2 million in Q1 2024.

• Quarterly Non-Current Deffered Revenue fell 76.56% year-over-year to $2.2 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $2.2 million (down 76.56% YoY) and the FY2023 annual result came in at $5.5 million, changed N/A from the prior year.
• Non-Current Deffered Revenue slipped to $2.2 million in Q1 2024, from $5.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $9.4 million in Q1 2023 to a low of $3000.0 in Q2 2021.
• A 4-year average of $2.3 million and a median of $12000.0 in 2021 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue jumped 50.0% — and 2024, when it tumbled 76.56%.
• Tracing IMNM's Non-Current Deffered Revenue over 4 years: stood at $8000.0 in 2020, then jumped by 50.0% to $12000.0 in 2021, then soared by 45641.67% to $5.5 million in 2023, then tumbled by 59.77% to $2.2 million in 2024.
• The last three Non-Current Deffered Revenue figures came in at $2.2 million (Q1 2024), $5.5 million (Q4 2023), and $2.9 million (Q3 2023), per Business Quant data.